Advertisement
Screener

BioXcel Therapeutics, Inc. (BTAI) Interest Income (Expense), Nonoperating, Net

2.8 / 5 stars · 68/120 Roast Me

BioXcel Therapeutics, Inc. Interest Income (Expense), Nonoperating, Net

BioXcel Therapeutics, Inc. (BTAI) reported Interest Income (Expense), Nonoperating, Net of -$2.88 million for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-14.

Discontinued › Income Statement › Other Income

us-gaap:InterestIncomeExpenseNonoperatingNet · last filed 2022-11-14

  • BioXcel Therapeutics, Inc. interest income (expense), nonoperating, net for the quarter ending 2022-09-30 was -$2.88M, a 287800.00% decline year-over-year.
  • BioXcel Therapeutics, Inc. interest income (expense), nonoperating, net for the quarter ending 2021-09-30 was $1.00K.
  • BioXcel Therapeutics, Inc. interest income (expense), nonoperating, net for the quarter ending 2020-06-30 was $16.00K, a 90.24% decline year-over-year.
  • BioXcel Therapeutics, Inc. interest income (expense), nonoperating, net for the quarter ending 2020-03-31 was $85.00K, a 60.47% decline year-over-year.
  • BioXcel Therapeutics, Inc. interest income (expense), nonoperating, net for fiscal 2019 was $633.00K, a 8.53% decline from fiscal 2018.
  • BioXcel Therapeutics, Inc. interest income (expense), nonoperating, net for fiscal 2018 was $692.00K.
  • BioXcel Therapeutics, Inc. interest income (expense), nonoperating, net for fiscal 2017 was -$2.00K.
Period endInterest Income (Expense), Nonoperating, Net 3 monthInterest Income (Expense), Nonoperating, Net 6 monthInterest Income (Expense), Nonoperating, Net 9 monthInterest Income (Expense), Nonoperating, Net 12 month
2022-09-30-$2.88M
10-Q · filed 2022-11-14
-$4.25M
10-Q · filed 2022-11-14
2021-09-30$1.00K
10-Q · filed 2022-11-14
-$2.00K
10-Q · filed 2022-11-14
2020-06-30$16.00K
10-Q · filed 2020-08-14
$101.00K
10-Q · filed 2020-08-14
$239.00K
derived: sum of 3 quarters · filed 2020-08-14
$355.00K
derived: sum of 4 quarters · filed 2020-08-14
2020-03-31$85.00K
10-Q · filed 2020-05-12
$223.00K
derived: sum of 2 quarters · filed 2020-05-12
$339.00K
derived: sum of 3 quarters · filed 2020-05-12
$503.00K
derived: sum of 4 quarters · filed 2020-08-14
2019-12-31$138.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09
$254.00K
derived: sum of 2 quarters · filed 2020-03-09
$418.00K
derived: sum of 3 quarters · filed 2020-08-14
$633.00K
10-K · filed 2020-03-09
2019-09-30$116.00K
10-Q · filed 2019-11-14
$280.00K
derived: sum of 2 quarters · filed 2020-08-14
$495.00K
10-Q · filed 2019-11-14
$733.00K
derived: sum of 4 quarters · filed 2020-08-14
2019-06-30$164.00K
10-Q · filed 2020-08-14
$379.00K
10-Q · filed 2020-08-14
$617.00K
derived: sum of 3 quarters · filed 2020-08-14
$849.00K
derived: sum of 4 quarters · filed 2020-08-14
2019-03-31$215.00K
10-Q · filed 2020-05-12
$453.00K
derived: sum of 2 quarters · filed 2020-05-12
$685.00K
derived: sum of 3 quarters · filed 2020-05-12
$903.00K
derived: sum of 4 quarters · filed 2020-05-12
2018-12-31$238.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09
$470.00K
derived: sum of 2 quarters · filed 2020-03-09
$688.00K
derived: sum of 3 quarters · filed 2020-03-09
$692.00K
10-K · filed 2020-03-09
2018-09-30$232.00K
10-Q · filed 2019-11-14
$450.00K
derived: sum of 2 quarters · filed 2019-11-14
$454.00K
10-Q · filed 2019-11-14
2018-06-30$218.00K
10-Q · filed 2019-08-06
$222.00K
10-Q · filed 2019-08-06
2018-03-31$4.00K
10-Q · filed 2019-05-07
2017-12-31-$2.00K
10-K · filed 2019-03-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
JUPITER NEUROSCIENCES, INC. (JUNS)United States$0.002B-0.02
ORAGENICS INC (OGEN)United States$0.002B
ZyVersa Therapeutics, Inc. (ZVSA)United States$0.002B
Nexentis Technologies Inc. (NXTS)$0.002B
Decoy Therapeutics Inc. (DCOY)United States$0.002B-0.27
Matinas BioPharma Holdings, Inc. (MTNB)United States$0.003B
Petros Pharmaceuticals, Inc. (PTPI)United States$0.003B
GeoVax Labs, Inc. (GOVX)United States$0.003B-0.45
Silo Pharma, Inc. (SILO)United States$0.003B-1.57
Genprex, Inc. (GNPX)United States$0.003B-0.02